Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and that can be difficult because UV-C is, in practical terms, an invisible tool.

Since the beginning of the pandemic, the world is acutely aware that infection control isn’t just for hospitals. Discussing these new use cases and how UV-C works, host Daniel Litwin spoke with Wendy Brady, Director of Global Marketing for Intellego Technologies.

“Pathogens are everywhere on the surfaces we touch and the air we breathe. UV-C can be an important tool to protect spaces outside of healthcare,” Brady said. But the key to successful UV-C disinfection is ensuring that you’ve delivered the right amount of ultraviolet irradiation to surfaces.

So, how exactly does UV-C light work?

“UV-C is part of the ultraviolet spectrum and it has a powerful germicidal effect on bacteria, viruses and fungi,” Brady explained. “The way it works is by breaking the DNA or RNA bonds in organisms so they can then no longer reproduce. It renders them inactive, but a sufficient amount of energy or irradiation must be delivered to surface in order to achieve a germicidal effect.”

With established and widespread use in hospitals, other industries are now looking to the technology to help combat pathogens and make public areas safer. Brady said that schools, airports, hotels, event venues, commercial office buildings and more are all beginning to employ different types of UV-C systems to provide a higher level of sanitization.

Because UV-C is often used in unoccupied spaces or in closed cabinet systems, it’s challenging for operators to know if their device is truly working and that all target areas have received enough irradiation to achieve sanitization. It’s not something they can see, but dosimeters provide that important piece of visible evidence.

UVC Dosimeters have a color-changing indicator area that shows the ‘dose’ or how much germicidal irradiation has been delivered. By seeing the dose, measured as 25, 50 or 100 mJ/cm², a person can verify that the device has delivered enough energy needed to kill SARS-CoV-2, MRSA or even C. Difficile,” Brady said.

With a dosimeter, users have accurate, visible confirmation and real-time evidence that a UV-C disinfection device has done its job. With this additional context, disinfecting can become a more efficient process and it builds confidence in the effectiveness of the technology.

“Dosimeters can also save time, as users can see when the disinfection cycle is successful. Operators are finding that some areas can be sanitized more quickly than expected because they can see when they’ve reached a target dose. This means they can use their UV-C equipment in a more efficient manner, sanitizing more areas and creating safer environments,” Brady added.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512